Astellas Pharma Inc (ALPMY)
9.34
+0.07
(+0.74%)
USD |
OTCM |
Apr 16, 15:59
Astellas Pharma Revenue (TTM): 10.99B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.99B |
| September 30, 2023 | 10.98B |
| June 30, 2023 | 11.02B |
| March 31, 2023 | 11.23B |
| December 31, 2022 | 11.17B |
| September 30, 2022 | 11.31B |
| June 30, 2022 | 11.52B |
| March 31, 2022 | 11.55B |
| December 31, 2021 | 11.85B |
| September 30, 2021 | 11.97B |
| June 30, 2021 | 11.92B |
| March 31, 2021 | 11.79B |
| December 31, 2020 | 11.74B |
| September 30, 2020 | 11.74B |
| June 30, 2020 | 11.78B |
| March 31, 2020 | 11.97B |
| December 31, 2019 | 11.83B |
| September 30, 2019 | 11.90B |
| June 30, 2019 | 11.80B |
| March 31, 2019 | 11.78B |
| December 31, 2018 | 11.82B |
| September 30, 2018 | 11.83B |
| June 30, 2018 | 11.84B |
| March 31, 2018 | 11.72B |
| December 31, 2017 | 11.64B |
| Date | Value |
|---|---|
| September 30, 2017 | 11.70B |
| June 30, 2017 | 11.91B |
| March 31, 2017 | 12.13B |
| December 31, 2016 | 12.10B |
| September 30, 2016 | 11.97B |
| June 30, 2016 | 11.72B |
| March 31, 2016 | 11.43B |
| December 31, 2015 | 11.23B |
| September 30, 2015 | 11.25B |
| June 30, 2015 | 11.32B |
| March 31, 2015 | 11.37B |
| December 31, 2014 | 11.54B |
| September 30, 2014 | 11.64B |
| June 30, 2014 | 11.54B |
| March 31, 2014 | 11.37B |
| December 31, 2013 | 11.20B |
| September 30, 2013 | 11.40B |
| June 30, 2013 | 11.59B |
| March 31, 2013 | 11.90B |
| December 31, 2012 | 12.03B |
| September 30, 2012 | 12.22B |
| June 30, 2012 | 12.23B |
| March 31, 2012 | 12.29B |
| December 31, 2011 | 12.36B |
| September 30, 2011 | 12.04B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
10.98B
Minimum
Sep 2023
11.97B
Maximum
Sep 2021
11.58B
Average
11.74B
Median
Dec 2020
Revenue (TTM) Benchmarks
| Daiichi Sankyo Co Ltd | 10.68B |
| Takeda Pharmaceutical Co Ltd | 29.70B |
| Nxera Pharma Co Ltd | 88.33M |
| PeptiDream Inc | 202.69M |
| Stemcell Holdings Inc | 9.984M |